Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235667 | 0.90 | ALDH1A1 (0.57) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL2471189 | 0.84 | MAPT (0.62) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL24320204 | 0.83 | GPR119 (0.48) | GPR119ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL22914742 | 0.81 | CTSS (0.46) | EGLN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24990167 | 0.81 | EGLN2 (0.63) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL3857712 | 0.81 | HPGD (0.56) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL28088874 | 0.81 | GPR119 (0.62) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL3486554 | 0.79 | GPR119 (0.73) | GPR119 | |
| SCHEMBL22914840 | 0.79 | GPR119 (0.51) | GPR119EGLN2ALDH1A1LMNAMAPT | |
| SCHEMBL20511213 | 0.79 | GPR119 (0.51) | GPR119EGLN2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | GPR119 1166/4885EGLN2 4307/4885ALDH1A1 4630/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | GPR119 1166/4885EGLN2 4307/4885ALDH1A1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.